Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00064298|
Recruitment Status : Completed
First Posted : July 9, 2003
Results First Posted : July 24, 2017
Last Update Posted : September 28, 2021
RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development or recurrence of cancer. Fruit and vegetable extracts may be effective in preventing the recurrence or further development of head and neck cancer.
PURPOSE: This randomized phase II trial is studying how well fruit and vegetable extracts work in preventing the recurrence of stage I, stage II, stage III, stage IVA, or stage IVB head and neck cancer.
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Cancer||Dietary Supplement: fruit and vegetable extracts Dietary Supplement: placebo||Phase 2|
- Compare the disease-free survival of patients with stage I-IV (including stage IVA and IVB) head and neck cancer treated with fruit and vegetable extracts vs placebo.
- Compare the effect of these extracts on biomarkers (p27 expression, cell proliferation of Ki-67, DNA damage, and T-cell function) in these patients.
- Correlate changes in biomarkers with other factors (e.g., site and stage of the original tumors, tobacco/alcohol use, or depression) in patients treated with these extracts.
- Compare serum carotenoids and antioxidant levels (vitamins A, C, and E) at baseline and posttreatment in patients treated with these extracts.
OUTLINE: This is a randomized, placebo-controlled, double-blind study. Patients are stratified according to tobacco use (yes vs no), alcohol consumption (yes vs no), and tumor stage at diagnosis (I vs II vs III vs IVA vs IVB). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral fruit and vegetable extracts twice daily.
- Arm II: Patients receive oral placebo twice daily. Treatment in both arms continues for 12 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed annually for 5 years.
PROJECTED ACCRUAL: A total of 200 patients (100 per treatment arm) will be accrued for this study within 18 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||134 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Phase II Randomized Placebo Controlled, Double Blinded Trial To Evaluate The Effects Of Fruit And Vegetable Extracts On Intermediate Biomarkers In Head And Neck Cancer Patients|
|Actual Study Start Date :||January 1, 2004|
|Actual Primary Completion Date :||October 1, 2008|
|Actual Study Completion Date :||April 1, 2009|
Experimental: Arm I - JuicePlus
Patients receive oral fruit and vegetable extracts twice daily.
Dietary Supplement: fruit and vegetable extracts
Placebo Comparator: Arm II - Control
Patients receive oral placebo twice daily.
Dietary Supplement: placebo
- Expression of p27 Cell Cycle Regulatory Protein at Baseline and Week 12 [ Time Frame: baseline and 12 weeks ]Expression of p27 cell cycle regulatory protein at baseline and week 12. p27 is measured continuously. Lower values are worse.
- Cell Proliferation (Ki-67) at Baseline and Week 12 [ Time Frame: baseline and 12 weeks ]Cell proliferation (Ki-67) at baseline and week 12. Ki67 is a cell proliferation associated nuclear protein. It is measured continuously. Higher values are worse.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00064298
|Study Chair:||Steven A. Akman, MD||Wake Forest University Health Sciences|